AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19604722 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin with docetaxel) followed by accelerated concomitant boost radiotherapy (44 Gy in 22 fractions) and definitive surgery
Number of subjects: 46
Study 19605490 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vaccinia virus Ankara/fowlpox virus-based HIV-1 vaccines
Number of subjects: 20
Study 19605831 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Number of subjects: 328
Study 19605831 — intervention group
Group type: COMPARATOR
Intervention: Optical colonoscopy
Number of subjects: 328
Study 19606043 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigileo cardiac output monitor
Number of subjects: 0
Study 19606043 — intervention group
Group type: EXPERIMENTAL
Intervention: LiDCOplus cardiac output monitor
Number of subjects: 0
Study 19608028 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flow rotary left ventricular assist device (LVAD)
Number of subjects: 281
Study 19608137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary NIRS system for detection of lipid core-containing plaques (LCP)
Number of subjects: 89
Study 19608137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary NIRS system
Number of subjects: 89
Study 19608533 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation using a prototype epiretinal prosthesis with a 4 x 4 array of 16 stimulating electrodes.
Number of subjects: 0
Study 19608533 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation using the prosthetic device.
Number of subjects: 0
Study 19608747 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative (MA) regimen with CD34(+) counts greater than 3.8 x 10(6)/kg
Number of subjects: 932
Study 19608747 — intervention group
Group type: EXPERIMENTAL
Intervention: All preparative regimens with CD34(+) cell doses exceeding 4.5 x 10(6)/kg
Number of subjects: 932
Study 19608747 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative (MA) regimen
Number of subjects: 932
Study 19608747 — intervention group
Group type: COMPARATOR
Intervention: Reduced-intensity (RI) and nonmyeloablative (NMA) regimens
Number of subjects: 932
Study 19608747 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity (RI) regimen
Number of subjects: 932
Study 19608747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative (NMA) regimen
Number of subjects: 932
Study 19608747 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CD34(+) cell doses
Number of subjects: 932
Study 19615094 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention study (PROMISE EBF)
Number of subjects: 877
Study 19615672 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking pregnant women (SPW)
Number of subjects: 59
Study 19615672 — intervention group
Group type: COMPARATOR
Intervention: Lifetime nonsmoking pregnant women (NSPW)
Number of subjects: 59
Study 19615940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg orally once daily on schedule 4-2 (4 weeks on treatment, 2 weeks off)
Number of subjects: 4371
Study 19616281 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily until disease progression
Number of subjects: 29
Study 19617402 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients whose family members returned surveys about end-of-life care
Number of subjects: 2016
Study 19617402 — intervention group
Group type: COMPARATOR
Intervention: Patients whose family members did not return surveys about end-of-life care
Number of subjects: 2016
Study 19618202 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT)
Number of subjects: 37
Study 19619781 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemosiderin foci present
Number of subjects: 48
Study 19619781 — intervention group
Group type: COMPARATOR
Intervention: No hemosiderin foci
Number of subjects: 48
Study 19619781 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hemosiderin foci
Number of subjects: 48
Study 19619781 — intervention group
Group type: EXPERIMENTAL
Intervention: Small stroke
Number of subjects: 48
Study 19619781 — intervention group
Group type: EXPERIMENTAL
Intervention: Periventricular leukomalacia
Number of subjects: 48
Study 19620489 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 or 36 Gy in 4-Gy fractions, given twice daily (36 Gy cohort with pure photons)
Number of subjects: 198
Study 19620489 — intervention group
Group type: EXPERIMENTAL
Intervention: ILV receiving 20 Gy or higher (ILV, 20 Gy) of 3% or higher
Number of subjects: 198
Study 19620489 — intervention group
Group type: EXPERIMENTAL
Intervention: ILV 10 Gy of 10% or higher
Number of subjects: 198
Study 19620489 — intervention group
Group type: EXPERIMENTAL
Intervention: ILV 5 Gy of 20% or higher
Number of subjects: 198
Study 19620516 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (1 g twice daily) for 24 weeks
Number of subjects: 32
Study 19621454 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 185
Study 19621454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 19624460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin injected subcutaneously (s.c.) twice daily at a median dose of 90 (73-106) units kg(-1) per 12 h
Number of subjects: 32
Study 19624460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin injected subcutaneously (s.c.) twice daily
Number of subjects: 32
Study 19625715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi vaccine
Number of subjects: 37673
Study 19625715 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine
Number of subjects: 37673
Study 19625715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi vaccine (children aged 2-5 years)
Number of subjects: 37673
Study 19625715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi vaccine (unvaccinated neighbors)
Number of subjects: 37673
Study 19625715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi vaccine (overall residents in clusters)
Number of subjects: 37673
Study 19628125 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous myocardial infarction (MI)
Number of subjects: 7773
Study 19628125 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural myocardial infarction (MI)
Number of subjects: 7773
Study 19628125 — intervention group
Group type: COMPARATOR
Intervention: No myocardial infarction (MI)
Number of subjects: 7773
Study 19628656 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day) for 18 months
Number of subjects: 14
Study 19628656 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan treatment
Number of subjects: 14
Study 19628656 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 14
Study 19629020 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 0
Study 19629020 — intervention group
Group type: COMPARATOR
Intervention: Pharmaceutical antidepressants
Number of subjects: 0
Study 19629020 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotic medications
Number of subjects: 0
Study 19629306 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS with ST-segment elevation
Number of subjects: 126
Study 19629306 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS (both groups)
Number of subjects: 126
Study 19629306 — intervention group
Group type: COMPARATOR
Intervention: Control group (blood donors without known coronary disease)
Number of subjects: 126
Study 19630971 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (epoietin-beta) at high doses (1,500 U/kg/day for three days) combined with quinine
Number of subjects: 35
Study 19630971 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (epoietin-beta) at high doses combined with quinine
Number of subjects: 35
Study 19631001 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department physician activation of the catheterization lab and immediate transfer to catheterization lab by in-house transfer team.
Number of subjects: 132
Study 19632952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 36
Study 19632975 — intervention group
Group type: EXPERIMENTAL
Intervention: American Indian or Alaskan Native (AI/AN)
Number of subjects: 45
Study 19632975 — intervention group
Group type: EXPERIMENTAL
Intervention: African American (AA)
Number of subjects: 45
Study 19632975 — intervention group
Group type: COMPARATOR
Intervention: Caucasian
Number of subjects: 45
Study 19633200 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy, bone marrow transplantation, or gene therapy in ADA-deficient neonatal mice
Number of subjects: 0
Study 19633200 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with ADA-transduced hematopoietic stem cells
Number of subjects: 0
Study 19633200 — intervention group
Group type: COMPARATOR
Intervention: Untreated ADA-severe combined immunodeficiency patients
Number of subjects: 0
Study 19635928 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of acid sphingomyelinase inhibitors (amitriptyline, trimipramine, desipramine, chlorprothixene, fluoxetine, amlodipine, sertraline)
Number of subjects: 0
Study 19635928 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 0
Study 19635928 — intervention group
Group type: COMPARATOR
Intervention: Diet with Peptamen
Number of subjects: 0
Study 19635999 — intervention group
Group type: EXPERIMENTAL
Intervention: NOTCH1 and FBXW7 mutations (MUT)
Number of subjects: 88
Study 19635999 — intervention group
Group type: EXPERIMENTAL
Intervention: NOTCH1 mutations (MUT)
Number of subjects: 88
Study 19635999 — intervention group
Group type: EXPERIMENTAL
Intervention: FBXW7 mutations (MUT)
Number of subjects: 88
Study 19635999 — intervention group
Group type: COMPARATOR
Intervention: Wild type (WT) for both markers
Number of subjects: 88
Study 19636002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, capecitabine, and radiation (50.4 Gy per 28 fractions, capecitabine 825 mg/m² orally twice daily on days of radiation, bevacizumab 5 mg/kg on days 1, 15, and 29, followed by maintenance gemcitabine 1 g/m² weekly for 3 weeks and bevacizumab 5 mg/kg every 2 weeks)
Number of subjects: 82
Study 19636002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, capecitabine, and radiation
Number of subjects: 82
Study 19636006 — intervention group
Group type: EXPERIMENTAL
Intervention: Talampanel with standard radiation (RT) and temozolomide (TMZ)
Number of subjects: 72
Study 19636006 — intervention group
Group type: EXPERIMENTAL
Intervention: Talampanel with RT + TMZ
Number of subjects: 72
Study 19636010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacetuzumab (2 mg/kg weekly for 4 weeks, with dose escalation up to 8 mg/kg)
Number of subjects: 50
Study 19638109 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation/aspirator device
Number of subjects: 16
Study 19638218 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial keloids
Number of subjects: 5
Study 19638905 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous mastectomy with nipple-areola skin conservation
Number of subjects: 96
Study 19640291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 602
Study 19640291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 19640956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status measured by 25-hydroxyvitamin D [25(OH)D] levels
Number of subjects: 58
Study 19640956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass (FM)
Number of subjects: 58
Study 19640956 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 58
Study 19640956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral content and bone mineral density
Number of subjects: 58
Study 19641161 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperspectral imaging of tissue oxyhemoglobin and deoxyhemoglobin
Number of subjects: 66
Study 19641201 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 4776
Study 19641201 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding
Number of subjects: 4776
Study 19641201 — intervention group
Group type: COMPARATOR
Intervention: Composite end point of 30-day major adverse outcomes
Number of subjects: 4776
Study 19641201 — intervention group
Group type: COMPARATOR
Intervention: Extreme values of body-mass index
Number of subjects: 4776
Study 19641201 — intervention group
Group type: COMPARATOR
Intervention: Age, sex, race, ethnic group, and other coexisting conditions
Number of subjects: 4776
Study 19641325 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone, 4 mg daily for 6 months
Number of subjects: 3
Study 19641325 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 3
Study 19643246 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery
Number of subjects: 54
Study 19643246 — intervention group
Group type: COMPARATOR
Intervention: Retained feeding tube
Number of subjects: 54
Study 19643246 — intervention group
Group type: COMPARATOR
Intervention: Complications
Number of subjects: 54
Study 19643318 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI at 1.5-T with specific absorption rate limited to 2 W/kg; ICDs reprogrammed pre-MRI
Number of subjects: 18
Study 19643318 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI at 1.5-T
Number of subjects: 18
Study 19643971 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MRI
Number of subjects: 80
Study 19643983 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous alemtuzumab
Number of subjects: 99
Study 19646269 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with 9-1-1 call takers to identify themes and belief categories
Number of subjects: 0
Study 19646269 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative survey designed based on qualitative results
Number of subjects: 0
Study 19646269 — intervention group
Group type: EXPERIMENTAL
Intervention: Final version of the quantitative survey administered to all registered call takers
Number of subjects: 0
Study 19648219 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and group therapy for 2 months
Number of subjects: 22
Study 19648219 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching videotape showing smoking scenes
Number of subjects: 22
Study 19648219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of urge to smoke while watching smoking scenes
Number of subjects: 22
Study 19648219 — intervention group
Group type: COMPARATOR
Intervention: Control movie
Number of subjects: 22
Study 19648970 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at 4.5 mg/m(2)/d combined with CY 1.5 g/m(2)/d and carboplatin 200 mg/m(2)/d
Number of subjects: 16
Study 19648970 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at 6.0 mg/m(2)/d combined with CY 1.5 g/m(2)/d and carboplatin 200 mg/m(2)/d
Number of subjects: 16
Study 19648970 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (various doses)
Number of subjects: 16
Study 19649755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfunctional adrenal incidentaloma (NFA) patients
Number of subjects: 35
Study 19649755 — intervention group
Group type: COMPARATOR
Intervention: Age, total cholesterol, presence of adrenal incidentaloma
Number of subjects: 35
Study 19650932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg
Number of subjects: 400
Study 19650932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg
Number of subjects: 400
Study 19650932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 70 mg
Number of subjects: 400
Study 19650932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 19651065 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical recombinant human thrombin (rThrombin) applied during surgical procedure (day 1)
Number of subjects: 209
Study 19651065 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical recombinant human thrombin (rThrombin)
Number of subjects: 209
Study 19652055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg orally twice daily until tumor progression or unacceptable toxicity
Number of subjects: 54
Study 19652067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralatrexate at a dose of 30 mg/m(2) weekly for 6 weeks every 7 weeks (MTD established in phase I/II study)
Number of subjects: 48
Study 19652067 — intervention group
Group type: COMPARATOR
Intervention: Pralatrexate at a dose of 135 mg/m(2) every other week
Number of subjects: 48
Study 19652199 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-retroviral vectors (RVs) gene therapy
Number of subjects: 2
Study 19652199 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2
Study 19652201 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacytidine and entinostat
Number of subjects: 0
Study 19652201 — intervention group
Group type: COMPARATOR
Intervention: Control group (de novo AML patients and normal CD34(+) bone marrow cells)
Number of subjects: 0
Study 19652630 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (Type 6/11/16/18)
Number of subjects: 3730
Study 19652630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study 19654407 — intervention group
Group type: EXPERIMENTAL
Intervention: MICA-mismatched patients
Number of subjects: 236
Study 19654407 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA 10/10 match with MICA mismatch
Number of subjects: 236
Study 19654407 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA any mismatch with MICA mismatch
Number of subjects: 236
Study 19654407 — intervention group
Group type: COMPARATOR
Intervention: MICA-matched patients
Number of subjects: 236
Study 19654407 — intervention group
Group type: COMPARATOR
Intervention: HLA 10/10 match without MICA mismatch
Number of subjects: 236
Study 19654407 — intervention group
Group type: COMPARATOR
Intervention: HLA any mismatch without MICA mismatch
Number of subjects: 236
Study 19656016 — intervention group
Group type: EXPERIMENTAL
Intervention: New teriparatide delivery device
Number of subjects: 199
Study 19657114 — intervention group
Group type: EXPERIMENTAL
Intervention: Interfant-99 protocol
Number of subjects: 30
Study 19659963 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin
Number of subjects: 249
Study 19659963 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Benefit Index for chronic hand eczema (PBI-HE)
Number of subjects: 249
Study 19660694 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) and spectroscopic (MRS) correlates of functional capacity
Number of subjects: 85
Study 19660694 — intervention group
Group type: EXPERIMENTAL
Intervention: PCr measurement
Number of subjects: 85
Study 19660694 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf muscle perfusion measurement
Number of subjects: 85
Study 19660694 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings from MRI and spectroscopy
Number of subjects: 85
Study 19661245 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal GER
Number of subjects: 304
Study 19661245 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal GER
Number of subjects: 304
Study 19661245 — intervention group
Group type: COMPARATOR
Intervention: No GER
Number of subjects: 304
Study 19663124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler, 400 microg/d for 8 weeks
Number of subjects: 11
Study 19663708 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccine booster
Number of subjects: 204
Study 19663708 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent HBV vaccination 4-5 years later
Number of subjects: 204
Study 19664276 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-1202
Number of subjects: 152
Study 19664276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 19664754 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous daclizumab (8 mg/kg at baseline, 4 mg/kg at week 2, 2 mg/kg every 4 weeks for 52 weeks)
Number of subjects: 6
Study 19664754 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous daclizumab
Number of subjects: 6
Study 19666119 — intervention group
Group type: EXPERIMENTAL
Intervention: IRL-1620 (1.6 microg/kg, i.v.)
Number of subjects: 0
Study 19666119 — intervention group
Group type: EXPERIMENTAL
Intervention: IRL-1620 (5.0 microg/kg, i.v.)
Number of subjects: 0
Study 19666119 — intervention group
Group type: EXPERIMENTAL
Intervention: IRL-1620 (15.0 microg/kg, i.v.)
Number of subjects: 0
Study 19666119 — intervention group
Group type: COMPARATOR
Intervention: ET(A) antagonist BMS187824 (5 mg/kg, i.v.) followed by IRL-1620 (5 microg/kg, i.v.)
Number of subjects: 0
Study 19667400 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-alloHSCT serum antibodies
Number of subjects: 0
Study 19667400 — intervention group
Group type: EXPERIMENTAL
Intervention: Human antibody-binding fragment (Fab) library
Number of subjects: 0
Study 19667400 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G1 (IgG1) converted Fab
Number of subjects: 0
Study 19669729 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-6 levels
Number of subjects: 33
Study 19669729 — intervention group
Group type: COMPARATOR
Intervention: Serum TNF-alpha or hsCRP levels
Number of subjects: 33
Study 19669729 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma DAG levels
Number of subjects: 33
Study 19669729 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating levels of ceramides and TNF-alpha
Number of subjects: 33
Study 19670189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) with de novo CNI minimization
Number of subjects: 100
Study 19670189 — intervention group
Group type: COMPARATOR
Intervention: Standard CNI-based immunosuppressive regimens (MMF group)
Number of subjects: 100
Study 19670189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) therapy
Number of subjects: 100
Study 19670189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus therapy
Number of subjects: 100
Study 19670189 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month estimated glomerular filtration rate (eGFR)
Number of subjects: 100
Study 19670189 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rejection
Number of subjects: 100
Study 19670912 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg infusion every 8 hours
Number of subjects: 1332